A study in Cell Death Discovery reported that an RNA chemical tag pathway involving m6A reader YTHDF2 can promote melanoma progression by destabilizing HMOX1 mRNA and shielding tumor cells from ferroptosis—while authors propose the vulnerability may be exploitable with metformin. In esophageal cancer, new work identified an R-loop–related gene signature associated with survival and immune landscape features, naming BRIX1, CHEK1, and NUP155 as core prognostic genes tied to tumor stemness and immune dysfunction. In triple-negative breast cancer models, researchers reported cells rely on shared DNA damage tolerance enzymes including POLζ and CHK1 across shifting phenotypic states; blocking those pathways, alone or with Olaparib, reduced chemoresistance in laboratory experiments. These findings add actionable biology to oncology pipelines by connecting post-transcriptional regulation, genome stress tolerance, and spatial immune context to predictable drug response strategies.